Ionis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.95), $0.17 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $134 million versus the consensus estimate of $129.33 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.